In this issue:
4-year outcomes of CheckMate 067 trial
Paediatric melanoma in melanoma-prone families
Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab
Adjuvant dabrafenib + trametinib in patients with resected BRAF V600– mutant stage III melanoma
FDG-PET response from anti-PD-1 therapy in metastatic melanoma
Economic cost of talimogene laherparepvec + ipilimumab vs ipilimumab in advanced unresectable melanoma
Phenotypic characteristics and UV radiation exposure and risk of melanoma on different body sites
Prognostic factors for metastatic uveal melanoma
Survival and cost of metastatic melanoma with new drugs
Please login below to download this issue (PDF)